Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Connect Biopharma stock | $17.17

Learn how to easily invest in Connect Biopharma stock.

Connect Biopharma Holdings Limited is a biotechnology business based in the US. Connect Biopharma shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Connect Biopharma employs 62 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Connect Biopharma

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CNTB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Connect Biopharma stock price (NASDAQ: CNTB)

Use our graph to track the performance of CNTB stocks over time.

Connect Biopharma shares at a glance

Information last updated 2021-10-10.
Latest market close$17.17
52-week range$14.02 - $29.00
50-day moving average $21.94
200-day moving average $19.65
Wall St. target price$29.31
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-7.98

Buy Connect Biopharma shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Connect Biopharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Connect Biopharma price performance over time

Historical closes compared with the close of $17.17 from 2021-10-15

1 week (2021-10-08) -6.43%
1 month (2021-09-16) -16.45%
3 months (2021-07-16) -21.95%
6 months (2021-04-16) -0.58%
1 year (2020-10-12) N/A
2 years (2019-10-12) N/A
3 years (2018-10-12) N/A
5 years (2016-10-12) N/A

Connect Biopharma financials

Gross profit TTM $0
Return on assets TTM -14.75%
Return on equity TTM -9999999%
Profit margin 0%
Book value $39.28
Market capitalisation $1.1 billion

TTM: trailing 12 months

Shorting Connect Biopharma shares

There are currently 854,558 Connect Biopharma shares held short by investors – that's known as Connect Biopharma's "short interest". This figure is 0.3% up from 851,674 last month.

There are a few different ways that this level of interest in shorting Connect Biopharma shares can be evaluated.

Connect Biopharma's "short interest ratio" (SIR)

Connect Biopharma's "short interest ratio" (SIR) is the quantity of Connect Biopharma shares currently shorted divided by the average quantity of Connect Biopharma shares traded daily (recently around 53915.331230284). Connect Biopharma's SIR currently stands at 15.85. In other words for every 100,000 Connect Biopharma shares traded daily on the market, roughly 15850 shares are currently held short.

To gain some more context, you can compare Connect Biopharma's short interest ratio against those of similar companies.

However Connect Biopharma's short interest can also be evaluated against the total number of Connect Biopharma shares, or, against the total number of tradable Connect Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Connect Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Connect Biopharma shares in existence, roughly 10 shares are currently held short) or 0.0657% of the tradable shares (for every 100,000 tradable Connect Biopharma shares, roughly 66 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Connect Biopharma.

Find out more about how you can short Connect Biopharma stock.

Connect Biopharma share dividends

We're not expecting Connect Biopharma to pay a dividend over the next 12 months.

You may also wish to consider:

Connect Biopharma overview

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. .

Frequently asked questions

What percentage of Connect Biopharma is owned by institutions?
Currently 33.197% of Connect Biopharma shares are held by institutions.
How many people work for Connect Biopharma?
Latest data suggests 62 work at Connect Biopharma.
When does the fiscal year end for Connect Biopharma?
Connect Biopharma's fiscal year ends in December.
Where is Connect Biopharma based?
Connect Biopharma's address is: East R&D Building, Taicang, China, 215400
What is Connect Biopharma's ISIN number?
Connect Biopharma's international securities identification number is: US2075231017

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site